Pointing to a growing demand for seasonal flu vaccines in Japan, Takeda has signed on with the Chemo-Sero Therapeutic Research Institute (Kaketsuken) to sell one of the institute's seasonal shots while it continues distribution of another.
In his debut earnings report since assuming his role as CEO of Japanese drugmaker Takeda, Christophe Weber had to tell investors today that the company had a small loss in its last fiscal year.
Turns out the FDA isn't the only one that's been ticked off with Orexigen since it released some early positive cardio data for obesity drug, Contrave, last March. Marketing partner Takeda is on that list, too--and earlier this week, the Japanese drugmaker went so far as to threaten to nix the pair's pact.
The FDA was none too happy with Orexigen when it put out some early positive cardio data for obesity drug Contrave in March. One reason? Early data can be misleading--and now, it looks like that might have been the case for Contrave.
Alisertib, a jewel of Takeda's $8.8 billion acquisition of Millennium Pharmaceuticals back in 2008, failed to make the grade in a Phase III lymphoma trial, forcing the Japanese drugmaker to pull the plug and pivot to other indications.
The pharmaceutical industry's producers and academic researchers in Japan are actively engaged, despite setbacks experienced by others such as Google, in building a big-data pipeline, this one now including 10 drugmakers and 30 medical institutions.
Takeda is preparing to pony up $2.3 billion to settle lawsuits accusing the Japanese pharma of hiding diabetes med Actos' cancer risks. But according to some experts, that's a steal.
Takeda has struck up a 10-year partnership with Japan's Kyoto University to develop potential stem cell treatments for an array of diseases, committing about $270 million to the effort.
Diabetes drugs of Takeda Pharmaceutical and AstraZeneca should be labeled at risk of heart failure associated with them, a group of U.S. FDA advisers recommended. Nearly all of the members of an advisory panel voted for the added safety information on labels.
Takeda has chosen a woman to run its U.S. pharma business, just weeks after new CEO Christophe Weber said he was unhappy with the gender balance in the Japanese drugmaker's management ranks. Weber recruited Eli Lilly USA exec Ramona Sequeira to replace Doug Cole, who announced his departure last November.